Llorca PM - Search Results

1

Immuno-metabolic profile of patients with psychotic disorders and metabolic syndrome. Results from the FACE-SZ cohort.

Foiselle M, Barbosa S, Godin O, Wu CL, Boukouaci W, Andre M, Aouizerate B, Berna F, Barau C, Capdevielle D, Vidailhet P, Chereau I, Davidovic L, Dorey JM, Dubertret C, Dubreucq J, Faget C, Fond G, Leigner S, Llorca PM, Mallet J, Misdrahi D, Martinuzzi E, Passerieux C, Rey R, Pignon B, Urbach M, Schürhoff F, Glaichenhaus N, Leboyer M, Tamouza R; FACE-SZ (FondaMental Academic Centers of Expertise for Schizophrenia) Groups. Foiselle M, et al. Among authors: llorca pm. Brain Behav Immun Health. 2022 Mar 29;22:100436. doi: 10.1016/j.bbih.2022.100436. eCollection 2022 Jul. Brain Behav Immun Health. 2022. PMID: 35469211 Free PMC article.

2

Tardive dyskinesias and antipsychotics: a review.

Llorca PM, Chereau I, Bayle FJ, Lancon C. Llorca PM, et al. Eur Psychiatry. 2002 May;17(3):129-38. doi: 10.1016/s0924-9338(02)00647-8. Eur Psychiatry. 2002. PMID: 12052573 Review.

3

[Prevention in schizophrenia].

Llorca PM, Denizot H. Llorca PM, et al. Therapie. 2008 May-Jun;63(3):251-5. doi: 10.2515/therapie:2008032. Epub 2008 Aug 23. Therapie. 2008. PMID: 18718215 Review. French.

4

The "Functional Remission of General Schizophrenia" (FROGS) scale: development and validation of a new questionnaire.

Llorca PM, Lançon C, Lancrenon S, Bayle FJ, Caci H, Rouillon F, Gorwood P. Llorca PM, et al. Schizophr Res. 2009 Sep;113(2-3):218-25. doi: 10.1016/j.schres.2009.04.029. Epub 2009 May 23. Schizophr Res. 2009. PMID: 19464855

5

Pharmacogenetic of response efficacy to antipsychotics in schizophrenia: pharmacodynamic aspects. Review and implications for clinical research.

Blanc O, Brousse G, Meary A, Leboyer M, Llorca PM. Blanc O, et al. Among authors: llorca pm. Fundam Clin Pharmacol. 2010 Apr;24(2):139-60. doi: 10.1111/j.1472-8206.2009.00751.x. Epub 2009 Aug 21. Fundam Clin Pharmacol. 2010. PMID: 19702693 Review.

6

Clinical predictors of response to olanzapine or risperidone during acute episode of schizophrenia.

Brousse G, Meary A, Blanc O, Lançon C, Llorca PM, Leboyer M. Brousse G, et al. Among authors: llorca pm. Psychiatry Res. 2010 Aug 30;179(1):12-8. doi: 10.1016/j.psychres.2009.03.003. Epub 2010 May 15. Psychiatry Res. 2010. PMID: 20472305 Clinical Trial.

7

Genetic and molecular exploration of UHMK1 in schizophrenic patients.

Dumaine A, Maucuer A, Barbet A, Manceau V, Deshommes J, Méary A, Szöke A, Schürhoff F, Llorca PM, Lancon C, Leboyer M, Jamain S. Dumaine A, et al. Among authors: llorca pm. Psychiatr Genet. 2011 Dec;21(6):315-8. doi: 10.1097/YPG.0b013e3283458a37. Psychiatr Genet. 2011. PMID: 21399567

8

The influence of therapeutic alliance and insight on medication adherence in schizophrenia.

Misdrahi D, Petit M, Blanc O, Bayle F, Llorca PM. Misdrahi D, et al. Among authors: llorca pm. Nord J Psychiatry. 2012 Feb;66(1):49-54. doi: 10.3109/08039488.2011.598556. Epub 2011 Aug 10. Nord J Psychiatry. 2012. PMID: 21830849

9

Validation of a functional remission threshold for the Functional Remission of General Schizophrenia (FROGS) scale.

Boyer L, Richieri R, Guedj E, Faget-Agius C, Loundou A, Llorca PM, Auquier P, Lançon C. Boyer L, et al. Among authors: llorca pm. Compr Psychiatry. 2013 Oct;54(7):1016-22. doi: 10.1016/j.comppsych.2013.04.008. Epub 2013 May 31. Compr Psychiatry. 2013. PMID: 23731897

10

A composite scale applied to evaluate anxiety in schizophrenic patients (SAES).

Llorca PM, Lancon C, Blanc O, de Chazeron I, Samalin L, Caci H, Lesturgeon JA, Bayle FJ. Llorca PM, et al. Eur Arch Psychiatry Clin Neurosci. 2014 Mar;264(2):171-8. doi: 10.1007/s00406-013-0416-1. Epub 2013 Jun 15. Eur Arch Psychiatry Clin Neurosci. 2014. PMID: 23771406

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

476 results

Search Page